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Abstract
Background: Trans-resveratrol rather than its biotransformed monosulfate metabolite exerts anti-medulloblastoma effects
by suppressing STAT3 activation. Nevertheless, its effects on human glioblastoma cells are variable due to certain unknown
reason(s).
Methodology/Principal Findings: Citing resveratrol-sensitive UW228-3 medulloblastoma cell line and primarily cultured rat
brain cells/PBCs as controls, the effect of resveratrol on LN-18 human glioblastoma cells and its relevance with metabolic
pattern(s), brain-associated sulfotransferase/SULT expression and the statuses of STAT3 signaling and protein inhibitor of
activated STAT3 (PIAS3) were elucidated by multiple experimental approaches. Meanwhile, the expression patterns of three
SULTs (SULT1A1, 1C2 and 4A1) in human glioblastoma tumors were profiled immunohistochemically. The results revealed
that 100 mM resveratrol-treated LN-18 generated the same metabolites as UW228-3 cells, while additional metabolite in
molecular weight of 403.0992 in negative ion mode was found in PBCs. Neither growth arrest nor apoptosis was found in
resveratrol-treated LN-18 and PBC cells. Upon resveratrol treatment, the levels of SULT1A1, 1C2 and 4A1 expression in LN-18
cells were more up-regulated than that expressed in UW228-3 cells and close to the levels in PBCs. Immunohistochemical
staining showed that 42.0%, 27.1% and 19.6% of 149 glioblastoma cases produced similar SULT1A1, 1C2 and 4A1 levels as
that of tumor-surrounding tissues. Unlike the situation in UW228-3 cells, STAT3 signaling remained activated and its protein
inhibitor PIAS3 was restricted in the cytosol of resveratrol-treated LN-18 cells. No nuclear translocation of STAT3 and PIAS3
was observed in resveratrol-treated PBCs. Treatment with STAT3 chemical inhibitor, AG490, committed majority of LN-18
and UW228-3 cells but not PBCs to apoptosis within 48 hours.
Conclusions/Significance: LN-18 glioblastoma cells are insensitive to resveratrol due to the more inducible brain-associated
SULT expression, insufficiency of resveratrol to suppress activated STAT3 signaling and the lack of PIAS3 nuclear
translocation. The findings from PBCs suggest that an effective anticancer dose of resveratrol exerts little side effect on
normal brain cells.
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Introduction
Glioblastoma multiforme (GM) is the most common primary
brain malignancy in human adults [1]. Irrespective to the com-
bination of surgical operation with improved external radiother-
apy and adjuvant chemotherapy, the prognosis of GMB remains
very poor due to its highly aggressive biological behavior and
frequent recurrence rate [2]. Therefore, exploring effective and
less toxic chemotherapeutic approaches would be of clinical values
in better management of this sort of lethal disease. So far, the data
about the effects of resveratrol on some human GM cell lines are
promising [3–5]. However, it remains largely unknown whether
resveratrol encounters resistance in GM cells and how normal
brain cells respond to this agent.
Resveratrol is a polyphenolic phytoalexin possessing a variety
of biological activities [6–8]. It is still obscure whether trans-
resveratrol or its metabolite(s) exerting the therapeutic effects [9],
however, this issue has been elucidated at least in part by our
recent findings from human medulloblastoma (MB) cells [10],
which revealed that trans-resveratrol was mainly biotransformed to
resveratrol monosulfates in MB cells but trans-resveratrol rather
than its monosulfate exerted anti-MB effects. The above findings
indicated that the declined sulfonation activity might prolong
the intracellular bioavailability and sustain anticancer efficacy of
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27484trans-resveratrol. To gain new insight into this issue, it would be
necessary to further address whether the metabolic pattern and/or
the metabolic activity of resveratrol are different in the sensitive
and resistant resveratrol treated cancer cells.
Citing UW228-3 MB cells as resveratrol-sensitive control and
primarily cultured 1-day-old Wistar rat brain cells (PBCs) as
normal control [11], the effects of resveratrol and its relevance
with metabolic pattern(s) and metabolite-associated gene expres-
sion in LN-18 GM cells were evaluated after the cells were treated
with resveratrol for 48 hours. Since STAT3 signaling was con-
sidered as the main molecular target of resveratrol in MB cells [12]
and the important survival factor for GM cells [13,14], the status
of this signaling, the expression of protein inhibitor of activated
STAT3 (PIAS3) and the effects of STAT3 chemical inhibitor
AG490 on LN-18 cells was investigated and the results were
compared with that obtained from UW228-3 and PBC cells.
Results
Differential resveratrol sensitivities
As shown in Figure 1A, LN-18 cells were spindle-like in shape,
which showed neither morphologic change nor apoptotic cell
death after 100 mM resveratrol treatment for 48 hours. Similarly,
100 mM resveratrol treated primarily cultured rat brain cells
including neurons and glial cells kept growth and showed no sign of
cell death. As the resveratrol-sensitive control, elliptical UW228-3
cells showed neuron-like morphology, synaptophisin expression
(upper insets for Figure 1A) and distinct apoptosis hallmarks (lower
insets for Figure 1A). 0.25% trypan blue viable/nonviable cell
discrimination assay revealed that after 100 mM resveratrol
treatment for 0, 12, 24, 36, and 48 hours, the percentage of
nonviable cells was 0.16%, 11.23%, 30.9%, 35.46%, and 42.86%
in UW228-3 cells, 0.19%, 1.21%, 5.63%, 8.71%, and 10.50% in
LN-18 cells and 0.21%, 1.19%, 1.66%, 1.83%, and 2.67% in PBC
cells. FCM analyses (Figure 1B) further demonstrated that G1 and
S fractions were 48.5% and 45.9% in normal UW228-3 cells and
changed to 97.6% and 1.2% in the resveratrol-treated cells. The
percentages of G1 and S phase LN-18 cells were 37.1% and
52.5% under normal culture condition and became 72.8% and
26.7% after 100 mM resveratrol treatment for 48 hour. In PBC
cells, G1 and S fractions were 54.5% and 32.9% in normal cells
and remained almost unchanged (53.7% and 35.0%) after
resveratrol-treatment. The percentages of apoptotic cells in
100 mM resveratrol-treated UW228-3, LN-18 and PBC cells were
18.1%, 0.1% and 1.1%, respectively. Because of the G1 arrest of
resveratrol-treated LN-18 cells and almost unchanged cell cycle
fractions in resveratrol-treated PBCs, LN-18 can be regarded as
resveratrol-insensitve and PBCs as resveratrol-resistant cells.
Resveratrol monosulfate detection in LN-18 cells
To identify the resveratrol metabolites in LN-18 cells, the cells
and the condition media were collected separately after 48-hour
Figure 1. Determination of resveratrol sensitivities of LN-18 and PBC cells to resveratrol. (A) H&E morphological staining performed on
UW228-3, LN-18 and PBC cells without (normal culture) and with 100 mM resveratrol treatment for 48 hours. The results of synaptophysin-oriented
ICC and TUNEL assay are shown in the upper and the lower insets for each of the main images, respectively. (B) Flow cytometry fractionation of cell
cycles and apoptotic cells in UW228-3, LN-18 and PBC cell populations without (NC) and with (Res) 100 mM resveratrol treatment for 48 hours.
*, indicates the peak of apoptotic cells.
doi:10.1371/journal.pone.0027484.g001
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ferer and subjected to HPLC and LC-MS/MS analyses.
Resveratrol-containing cell-free medium and the same kinds of
samples from UW228-3 and PBC cells were used as controls.
HPLC analyses revealed three major compounds in LN-18 cell
lysate and condition medium, which were resveratrol standard
(trans-resveratrol), cis-resveratrol and resveratrol monosulfate as
that found in UW228-3 samples [10], according to their retention
time in HPLC (Figure 2A), molecular weight in MS and HRMS
(Figure 2B) [15]. In addition to the above three compounds,
another major metabolite in the retention time of 11.96 minutes
(tR=11.96) and molecular weight of 403.0992 in negative ion
mode was detected in the lysate and condition medium of PBC
cells (Figure 2A), suggesting the variable resveratrol metabolic
patterns between rat and humans.
Resveratrol upregulated SULT expression
Since SULT1A1, 1C2 and 4A1 were preferably expressed in
human and rodent brains [16–18], the responsibility of the three
SULTs for resveratrol sulfonation was evaluated by checking their
statuses in LN-18 cells before and after resveratrol treatment by
immunocytochemical (ICC) staining and Western blotting. As
Figure 2. The metabolic patterns analyses of resveratrol in LN-18 and PBC cells. (A) The MS/MS spectrum of M1, M2 and M3 correspond to
1, 2 and 3 of the HPLC peaks. 4, an unidentified compound produced predominantly in PBCs. (B) Shimadzu LCMS-IT-TOF-based HRMS analysis of
resveratrol metabolites in LN-18 cells and PBCs. Arrows labeled as trans-resveratrol, cis-resveratrol, resveratrol monosulfate and resveratrol
glucuronide? indicate the exact [M–H]
- molecular ion weight of 227.0698 (C14H11O3, calculated m/z 227.0708), 227.0697 (C14H11O3, calculated m/z
227.0708), 307.1105 (C14H11SO6, calculated m/z 307.0276) and 403.0992 (C20H19O9, calculated m/z 403.1035), respectively.
doi:10.1371/journal.pone.0027484.g002
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4A1 were expressed in high levels in the PBC cells, and the reverse
also held true in UW228-3 cells. In the case of LN-18 cells,
SULT1A1 and 1C2 were expressed in low and SULT4A1 in ex-
tremely low levels. After resveratrol treatment, SULT4A1 became
detectable, SULT1C2 and, especially, SULT1A1 were enhanced
in LN-18 cells (Figure 3). The densitometry scan of Western blot
results revealed that the total three SULT level in resveratrol-
treated LN-18 cells was about 1.63 folds higher than that
produced by its normally cultured counterpart, 1.44 folds higher
than that in resveratrol-treated UW228-3 cells and about 86.3% as
much as that in resveratrol-treated PBC cells (Figure 3B).
Although SULT1A1, 1C2 and 4A1 levels were enhanced as well
in resveratrol-treated UW228-3 cells, the extents were 31.6%
lower than that of LN-18 cells (Figure 3B).
Variable brain-associated SULT expression in GM tissues
TMA-based immunohistochemical (IHC) staining showed that
SULT1A1, 1C2 and 4A1 expression in the brain tissues sur-
rounding MBs and GMs were as high as the levels in normal rat
brain, while in the case of GMs, the levels of SULT1A1, 1C2 and
4A1 expression were highly variable (Figure 4A; Table 1). The
expression patterns of these SULT genes among 149 GM cases
and 48 tumor-surrounding brain tissues were classified as
undetectable (2), decreased (+) and unchanged levels (.++) and
their frequencies were summarized in Table 1. It was found that
of 149 GM cases, 42.0%, 27.1% and 19.6% showed similar
SULT1A1, 1C2 and 4A1 levels (.++) as that of tumor-
surrounding tissues and the remaining parts showed reduction
(+) and even absence (2) of SULT1A1, 1C2 and 4A1 expression.
STAT3 and PIAS3 in the three types of cells
T h ep o t e n t i a li n f l u e n c eo fr e s v e r a t r o li nS T A T 3s i g n a l i n gw a s
evaluated by checking the expression and intracellular distribution of
STAT3 and PIAS3. As shown in Figure 5, STAT3 signaling was in
activated status in normally cultured LN-18 cells because of the
presence of STAT3 in both cytosolic space and the nuclei, and this
situation remained unchanged after 48 hours resveratrol treatment
(Figure 5B). Similarly, PIAS3 was constitutively expressed and
distributed in the cytoplasm regardless of resveratrol treatment
(Figure 5C). In resveratrol-sensitive UW228-3 cells, STAT3 expres-
sion was down-regulated accompanied with infrequent STAT3
nuclear translocation (insets for Figure 5A and 5B); reversely, PIAS3
was found in the cytoplasm of UW228-3 cells but translocalized into
the nuclei upon resveratrol treatment (insets for Figure 5C). In the
case of PBCs, both STAT3 and PIAS3 were localized in cytosol
regardless of resveratrol treatment (Figure 5B and 5C).
AG490 caused growth arrest and apoptosis of LN-18 but
not PBCs cells
To determine the correlation of the unchanged STAT3 acti-
vation with resveratrol insensitivity of human GM cells, 60 mM
AG490, a selective inhibitor of STAT3 phosphorylation, was used
Figure 3. Resveratrol upregulated SULT1A1, 1C2 and 4A1 expression. (A) ICC evaluation of SULT1A1, 1C2 and 4A1 expression in PBC,
UW228-3 and LN-18 cells without (N) and with (R) resveratrol treatment. (B) Western blot analyses of SULT1A1, 1C2 and 4A1 expression in LN-18 cells
without (N) and with (R) resveratrol treatment and compared with that in normal control PBCs and resveratrol-sensitive control medulloblastoma
UW228-3 cells. b-actin was used as loading control and for calculation of SULT expression levels/densitometry scan of Western blotting results.
*Compared with normal cultured LN-18 and UW228-3 cells, respectively; *represents statistical significance (p,0.05).
doi:10.1371/journal.pone.0027484.g003
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ing of LN-18 cells demonstrated that as similar as the situation in
UW228-3 cells (data not shown), STAT3 nuclear translocation
was distinctly inhibited by AG490 (Figure 6A), accompanied with
remarkably decreased fraction of G1 phase cells (2.6%) and
increased apoptotic cell death (8.1%; Figure 6B). In contrast,
AG490 exerted little effect on the growth and survival of PBCs
(Figure 6). Additionally, LN-18 cells treated with AG490 and
resveratrol combination (AG490/Res) showed more or less up-
regulated SULT1A1, 1C2 and 4A1 expression but did not
undergo more severe cell crisis than that caused by AG490 alone
(Figure 6C), suggesting the importance of STAT3 signaling in the
survival of LN-18 cells, STAT3 signaling as the major molecular
target of resveratrol and no influence of STAT3 inhibition in
reseveratrol regulated SULT expression.
Discussion
Trans-resveratrol has been increasingly recognized as an ideal
cancer therapeutic agent, because of its nontoxic property and
cancer preventive activities in a variety of human and rodent
cancers [19,20]. Trans-resveratrol can be biotransformed intracel-
lularly, generating one or more metabolites in cell type related
patterns [21–23]. Therefore, determination of the bioactive form(s)
of resveratrol in individual cell and cancer types becomes a
fundamental issue for successful application of this compound in
preventive and clinical medicine. In this context, a comparison of
resveratrol metabolic patterns in resveratrol-sensitive and -resistant
cancer cells would be helpful to figure out this issue. MB cells
including UW228-3 were sensitive to resveratrol [10,11]. Our
current study clearly demonstrates for the first time that human
LN-18 GM cells are insensitive and rat PBC cells are resistant to
resveratrol. The distinct responses of these three types of cells to
resveratrol thus provides an ideal model to shed light on the
underlying reasons leading to different therapeutic outcomes of
resveratrol in malignant and normal brain cells.
It was found that trans-resveratrol rather than its biotransformed
form, resveratrol monosulfate, exhibited anti-MB effects and that
the metabolic activity mediated by brain-associated SULTs was
Figure 4. The expression of SULT1A1, 1C2 and 4A1 in glioblastomas tissues. Immunohistochemical illustration of differential expression
patterns of SULT1A1, 1C2 and 4A1 in two cases of glioblastomas (GM). Medulloblastoma (MB) and its surrounding noncancerous cerebellum tissue
(NC) were cited as controls.
doi:10.1371/journal.pone.0027484.g004
Table 1. Immunohistochemical profiling of SULT expression in human brain tissues.
Samples No. SULT1A1 (%) SULT1C2 (%) SULT4A1 (%)
-$ + .++ - + .++ - + .++
Tissue specimens 197
Noncancerous 48 0 (0) 10 (62.5) 6 (37.5) 0 (0) 7(43.7) 9(56.3) 0 (0) 0 (0) 16 (100)
glioblastomas 149 5 (10.0) 24(48.0) 21 (42.0) 4 (8.3) 31 (64.6) 13(27.1)* 27(52.9) 14(27.5) 10 (19.6)*
*represents statistical significance (p,0.05).
*compared with noncancerous tumor surrounding tissues.
$-, undetectable immuno-labeling; +, positive but decreased immuno-labeling; ++, strong immuno-labeling.
doi:10.1371/journal.pone.0027484.t001
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that the metabolic pattern and/or metabolic efficiency of res-
veratrol might be different between resveratrol-sensitive and -
resistant cancer cells. To clarify this point, the combination of
HPLC, LC-MS/MS and HRMS techniques was used to com-
pare the resveratrol metabolite(s) in UW228-3, LN-18 and PBC
cells. Like the situation in resveratrol-sensitive UW228-3 cells,
resveratrol monosulfate is identified as the major metabolite in
LN-18 cells. Although both trans- and cis-resveratrol can be meta-
bolized to monosulfate forms [22,24], the monosulfate metabolite
in LN-18 cells may be mainly generated from trans-resveratrol,
because we prepared trans-resveratrol solution freshly and han-
dled it carefully during the experiment to minimize trans- to cis-
resveratrol transition. Resveratrol-resistant PBC cells shared
similar metabolites with the above two cell lines, but a compound
in the retention time of 11.96 minutes rather than resveratrol
monosulfate became predominant in the cell lysate and condition
medium. Although the additional metabolite of molecular weight
of 403.0992 in negative ion mode remains to be further chara-
cterized, the above findings suggest that the resveratrol metabolic
pattern by itself seems to follow a tissue- and even species-specific
fashions, therefore, may be unnecessarily related with the chemo-
sensitivities of primary brain tumors.
Resveratrol monosulfate is the metabolite of phase II sulfona-
tion reaction mediated by SULTs. The anti-MB effects of 100 mM
trans-resveratrol were apparently attenuated when a great fraction
of it was biotransformed to monosulfate [10,22], reflecting a
reverse relationship of SULT expression with resveratrol bioac-
tivity. This notion has been further supported by our more recent
finding that rat PBCs even tolerate as high as 200 mM resveratrol
treatment (Shu XH et al. Unpublished data). Since SULT1A1,
1C2 and 4A1 are preferably expressed in the rodent brain [16-18],
their expression levels in LN-18 without and with resveratrol
treatment was analyzed and compared with that in UW228-3 cells
and PBC cells. Although the baseline levels of the three brain-
associated SULTs in LN-18 and UW228-3 cells were much lower
than that in PBC cells, SULT1A1 and 1C2 upregulation was more
distinct in resveratrol-treated LN-18 cells. This phenomenon
indicates 1) that the brain-associated SULTs may be more
upregulatable in GM cells and 2) that the sulfonation activity in
LN-18 cells would be higher than that in UW228-3 cells. In
agreement with the in vitro findings, tissue microarray-based IHC
for the three brain-associated SULTs revealed diverse SULT
expression patterns in 149 GM cases of which 42.0%, 27.1% and
19.6% showed similar levels of SULT1A1, 1C2 and 4A1 as that of
tumor surrounding tissues. Since SULT-mediated sulfonation
reduces resveratrol bioactivity via modifying resveratrol’s chemical
structure, the unchanged in vivo expression levels and more
upregulatable features of SULTs may be unfavorable for main-
taining an effective dose of resveratrol in GM cells. In agreement
with this notion, the overall SULT level of resveratrol-resistant
PBC cells was high and two types of resveratrol metabolites were
generated.
Resveratrol possesses multiple molecular effects on cancer cells
in dose-dependent fashion and STAT3 signaling is one of its
molecular targets [12,25]. The case also holds true in resveratrol-
treated MB cells in which STAT3 signaling and its downstream
gene expression are concurrently inhibited [26]. Since STAT3
Figure 5. Evaluation of STAT3 and PIAS3 statuses in UW22-3, LN-18 and PBC cells. STAT3-oriented RT-PCR (A), immunocytochemical and
immunofluorescent illustration of intracellular distribution of STAT3 (B) and its inhibitor PIAS3 (C) in LN-18 cells without (N) and with (R) 100 mM
resveratrol treatment. Immunofluorescence results were shown in the insets for Fig 5B and 5C. Corresponding data obtained from PBC and UW228-3
cells were used as controls.
doi:10.1371/journal.pone.0027484.g005
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of this signaling in LN-18 and PBC cells without and with
resveratrol treatment were elucidated. It was revealed that STAT3
activation was found in LN-18 but not PBC cells under normal
culture condition. Unlike the situation in UW228-3 cells, STAT3
signaling in resveratrol-treated LN-18 cells remained activated in
terms of the presence of nuclear translocation and constant
expression of STAT3. These data indicates that the lack of re-
sponse of this signaling to resveratrol in LN-18 cells may be linked
with resveratrol insensitivity and the insufficient intracellular trans-
resveratrol bioavailability. This speculation is further supported by
the following findings: 1) neither STAT3 activation nor cellular
crisis is observed in PBC cells with high resveratrol biotransfor-
mation activities and 2) AG490 by itself is sufficient to induce
significant cell death of LN18 cells.
Protein inhibitor of activated STAT3 (PIAS3) negatively regu-
lates STAT3 activation [28,29] and the loss of PIAS3 in GM cells
contributes to enhanced STAT3 transcriptional activity and
subsequent cell proliferation [28,30]. Therefore, the relevance of
PIAS3 with resveratrol cytotoxic effects was investigated by the use
of UW228-3, LN-18 and PBS cells. The results revealed that
PIAS3 was expressed in those cells and distributed in the cyto-
plasm under normal culture condition. On exposure to resveratrol,
apparent PIAS3 nuclear translocation accompanied with reduced
STAT3 nuclear immuno-labeling was observed in resveratrol-
sensitive UW228-3 cells, while PIAS3 was restricted in the cyto-
solic space of resveratrol-insensitive LN-18 cells regardless of
STAT3 nuclear translocation. In the case of resveratrol-resistant
PBCs, neither PIAS3 nor STAT3 showed nuclear translocation.
Since PIAS3 exerts a profound inhibitory effect on STAT3-
mediated transcription of target promoters in nucleus [29], our
findings indicate a potential correlation of PIAS3 nuclear trans-
location or the presence of nuclear STAT3 with the fate of
resveratrol-treated cells. Therefore, it is reasonable to suppress
Figure 6. Sensitivities of LN-18 and PBC cells to STAT3 inhibitor AG490. (A) Immunofluorescence illustration of intracellular distribution of
STAT3 in LN-18 and PBC cells without (N) and with (AG490) 60 mM AG490 treatment. Arrows indicate the cells shown in the insets in high
magnification (X400). (B) Flow cytometry analysis revealed reduction of G1-phase cells, accumulation of S-phase cells and induction of apoptosis (blue
peak) in AG490-treated LN-18 cell population. The cell cycle progression was almost unchanged in PBC cells. *, indicates the peak of apoptotic cells.
(C) H&E morphologic examination of LN-18 cells under normal culture or incubated with 100 mM trans-resveratrol, 60 mM AG490 or resveratrol/AG490
mixture for 48 hours (Main images). Small images: immunocytochemical illustration of SULT1A1, 1C2 and 4A1 expression in LN-18 cells treated by
60 mM AG490 without/with 100 mM resveratrol supplementation. Normally cultured and 100 mM resveratrol-treated LN-18 cells were cited as
controls.
doi:10.1371/journal.pone.0027484.g006
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with STAT3 chemical inhibitor, AG490.
Taken together, our current study demonstrates that LN-18
GM cells share similar resveratrol metabolites with UW228-3 MB
cells regardless of the differences of their resveratrol sensitivities.
The expression levels of brain-associated SULTs are higher in
resveratrol-insensitive LN-18 and especially PBC cells than that in
resveratrol-sensitive UW228-3 MB cells. Consequently, the rela-
tively high efficiency of trans-resveratrol biotransformation, the
lack of response of STAT3 signaling to resveratrol and the rarity of
nuclear translocation of PIAS3 may confer resveratrol-insensitive
properties on LN-18 cells. Given the evidence of differential
SULT expression patterns in human GMs, evaluations of meta-
bolic activity and the sensitivity of STAT3 signaling to resveratrol
would be of potential values in individualized application of
resveratrol in the management of GMs. The findings from PBCs
suggest that an effective anticancer dose of resveratrol has little
side-effect on normal brain cells.
Materials and Methods
Primary rat brain cell culture
Two 1-day-old Wistar rats were obtained from the Experimen-
tal Animals Center of Dalian Medical University. The rat brains
were freshly removed and minced with a scalpel and triturated in
high glucose DMEM (Gibico, Invitrogen Corporation, Grand
Island, NY, USA). After centrifugation at 2000 rpm for 5 minutes,
the brain cells were washed with DMEM and centrifugated for
5 minutes. The cell suspensions were plated to 60 mm dishes
(Nunc A/S, Rosklide, Denmark) and cultured in high glucose
DMEM supplemented with 10% FBS under 37uC and 5% CO2
condition. 14 days later, the cells were used for experimental
purposes. All experimental protocols had been reviewed and
approved by the ethics committee of Dalian Medical University
(ECDMU-09066) for protection of human subjects and experi-
mental animals before conducting the project.
Cellular effects of resveratrol
LN-18 human GM cell line [31] and UW228-3 human MB cell
line [32] were cultured in DMEM (Gibco, USA) containing 10%
fetal bovine serum (Gibco, USA) under 37uC and 5% CO2
condition. UW228-3, LN-18 cells and PBCs were treated by
100 mM resveratrol respectively for 48 hours. The total cell
numbers and viability of the three cell lines with or without res-
veratrol treatment were determined with 0.25% trypan blue
(Sigma Chem Co., St. Louis, MO, USA). Meanwhile, cell-bearing
coverslips were harvested and fixed properly for H&E staining
(hematoxylin and eosin staining), TUNEL (terminal deoxynucleo-
tidyl transferase mediated nick end labeling; Promega Corp.,
Madison, WI, USA) assay and immunocytochemical staining for
SULTs and neuronal differentiation marker synaptophisin. FCM
(flow cytometry) was conducted to evaluate the effects of
resveratrol on cell growth and survival. The cells cultured in
conventional medium with 0.2% DMSO supplementation were
used as controls. Each of experimental groups was set in triplicate,
and the experiments were repeated at least three times to establish
confidential conclusions.
Identification of resveratrol metabolites
After 100 mM resveratrol treatment for 48 hours, the cell lysates
and the conditional media were prepared from LN-18, UW228-3
and PBC cells by the methods described elsewhere [10]. They
were purified and concentrated by Cleanert PEP-SPE cartri-
dges (60mg; Agela Technol Inc. PA, USA) for HPLC analysis.
Structural identification of resveratrol metabolite(s) generated by
resveratrol-treated cells was performed on cell lysates and con-
dition media respectively using LC/MS system (Applied Biosys-
tem/MDS SCIEX, Foster City, CA, USA). Accurate masses were
conducted by the use of high resolution mass spectrometry
(HRMS, Shimadzu Co., Kyoto, Japan) analysis [10].
In vitro and in vivo expression of brain-associated
sulfotransferases (SULTs)
ICC staining and Western blot analysis were performed on the
samples obtained from each of the experimental groups using the
rabbit anti-human SULT1A1, 1C2 and 4A1 antibodies (Protein-
Tech Group, Inc., Chicago, USA) by the method described
elsewhere [10–12]. The results were compared with that obtained
from UW228-3 MB cells (as resveratrol-sensitive control) and
PBCs (as normal control).
For IHC staining, 149 GM surgical specimens were collected
from the First Affiliated Hospital of Dalian Medical University and
Anshan Central Hospital, Anshan, China, after getting patients’
consent. They were incised from the tumor mass and, where
possible, tumor-surrounding tissues. The SULT1A1, 1C2 and 4A1
were selected for IHC because of their preferential expression in
brain [16–18]. At least three pathologists blind to the sample are
involved in the semi-quantitative analysis of the staining results
according to the labeling intensity, and scored as negative (2)i fn o
immuno-labeling was observed in target cells, weakly positive (+)i f
the labeling was faint, and moderately to strongly positive (.++)
when the labeling was stronger or distinctly stronger than (+).
Evaluation of STAT3 activation and PIAS3 expression
Activated STAT3 signaling is crucial for the growth and
survival of both MBs and GMs [33,34] and is supposed to be the
major molecular target of resveratrol [35]. Therefore, the potential
influence of resveratrol in STAT3 signaling was evaluated by
checking the expression and intracellular distribution of STAT3
and its protein inhibitor PIAS3 in LN-18 cells before and after
resveratrol treatment. ICC and immunofluorescence (IF) stain-
ing were performed on the coverslips obtained from each of the
experimental groups. The antibodies against STAT3 and PIAS3
were used according to the manufacturer’s instruction (Santa Cruz
Biotech, Inc, CA, USA). Meanwhile, total cellular RNAs were
prepared from LN-18 cells without and with resveratrol treatment
for paralleled RT-PCR by the use of STAT3 primers (f: 59-
GGGTGGAGAAGGACATCAGCGGTAA-39 and r: 59-GCCG-
ACAATACTTTCCGAATGC-39) and m-actin (f: 59-GCATG-
GAGTCCTGTGGCAT-39 and r: 59-CATGAAGCATTTGC-
GGTGG-39) [12]. The corresponding samples obtained from
UW228-3 cells were used as control.
Inhibition of STAT3 activation with AG490
AG490 (Sigma), a JAK2-specific inhibitor, was dissolved in
DMSO to a stock concentration of 50 mM and was diluted to the
final concentration of 60 mM with conventional culture medium
just before use. Four experimental groups were set as follows:
Group 1, normal culture; Group 2, 2% DMSO treatment as
background control; Group 3, treatment with 60 mM AG490;
Group 4, combination treatment with 60 mM AG490 and 100 mM
resveratrol. For morphologic evaluation, ICC and IF staining, the
coverslips were put into the dishes before initial cell seeding and
were collected after 48 hours treatment, using the antibodies
against STAT3 (Santa Cruz, CA). FCM was conducted to
evaluate the effects of AG490 on cell growth and survival.
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The experimental data were expressed as mean 6 SD. Mann-
Whitney tests were used to analyze the statuses of SULT1A1, 1C2
and 4A1 expression in different histological groups and expressed
in p-values. Statistical significance can be established if the p-value
is less than 0.05.
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